Ezose Sciences Announces Appointment of Chief Operating Officer
News Jun 26, 2012
Ezose Sciences Inc. announced that Scott A. Siegel, Ph.D., Vice President, Business Development, has been named Chief Operating Officer, a new position at the company.
Dr. Siegel will assume broad responsibility for operations at Ezose, which focuses on glycomics research to identify biomarkers for use in drug development and disease management, and to characterize biotherapeutic glycoforms. He will also continue to lead Business Development. In his new role he will continue to report to Kiyoshi Nagata, Ph.D., Chairman and Chief Executive Officer of Ezose.
"Scott has made Ezose a partner of choice for healthcare companies and academic institutions that seek to realize the promise of glycomics in their R&D programs," said Dr. Nagata. "At the same time, his talents and energies have already supported various operational activities at Ezose. We look forward to the still broader contributions he will make in his new position.
"The naming of a chief operating officer, together with the other appointments we are announcing today, demonstrates our commitment to helping our partners establish glycomics as a basic tool in their biomedical research."
Dr. Siegel brings to his role more than 25 years of experience in the biotechnology and pharmaceutical industries. Before joining Ezose in 2009 he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company. Earlier, he held various positions in New Business Development and Worldwide Strategic Marketing at Johnson & Johnson. He has served in R&D capacities at Phytera, Inc., Centocor, Inc., and Becton Dickinson and Co., and as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade(R) (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders.
Dr. Siegel earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
In other recent appointments, Ezose named:
-- Diane McCarthy, Ph.D., Director, Scientific Affairs. Dr. McCarthy was previously a longtime consultant to Ezose. She has held various leadership positions in the biotechnology industry, particularly in the field of proteomics and biomarkers. She earned a doctorate in Biochemistry at the University of Texas at Austin.
-- Ezra Jennings, Ph.D., Senior Scientist. Dr. Jennings has developed bioinformatics tools as a consultant to the Whitehead Institute for Biomedical Research and as a senior scientist at a biotech company focusing on diagnostics. He has a doctorate in Biology from the Massachusetts Institute of Technology.
-- Joshua Alfaro, Ph.D., Scientist. Dr. Alfaro has conducted various research projects in academic and government laboratories, including development of glycopeptide-enrichment methods. His doctorate in Organic Chemistry was earned at Washington State University
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
Agilent Technologies Presents Thought Leader Award to Dr. Ram SasisekharanNews
Agilent Technologies awards Dr. Ram Sasisekharan with the Agilent Thought Leader Award in recognition of his contributions in the field of biologics characterization.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBO Workshop: Integrating Systems Biology: From Networks to Mechanisms to Models
Apr 15 - Apr 17, 2018
EMBL Course: Introduction to Metabolomics Analysis
Mar 20 - Mar 23, 2018